Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Acquires $95,548.70 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 4,355 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were bought at an average cost of $21.94 per share, for a total transaction of $95,548.70. Following the completion of the purchase, the insider directly owned 641,685 shares of the company’s stock, valued at $14,078,568.90. The trade was a 0.68% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc acquired 731 shares of Surrozen stock. The shares were purchased at an average cost of $21.38 per share, for a total transaction of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The stock was purchased at an average price of $21.39 per share, for a total transaction of $91,356.69.

Surrozen Stock Performance

NASDAQ SRZN opened at $21.25 on Friday. The stock has a market capitalization of $182.11 million, a P/E ratio of -0.95 and a beta of 0.58. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $25.47. The stock has a fifty day moving average of $20.81 and a 200-day moving average of $15.14.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The firm had revenue of $0.98 million during the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. Equities research analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Surrozen

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its position in shares of Surrozen by 50.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock valued at $34,000 after buying an additional 500 shares in the last quarter. Citadel Advisors LLC grew its stake in Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after acquiring an additional 3,424 shares during the period. Geode Capital Management LLC grew its stake in Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares during the period. Woodline Partners LP bought a new stake in shares of Surrozen in the third quarter worth about $621,000. Finally, Armistice Capital LLC acquired a new stake in shares of Surrozen during the second quarter worth about $536,000. 66.57% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Wall Street Zen raised Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Surrozen has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.